Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M127,036Revenue $M42,159Net Margin (%)12.3Z-Score0
Enterprise Value $M127,036EPS $1.8Operating Margin %17.3F-Score0
P/E(ttm))24.9Cash Flow Per Share $0Pre-tax Margin (%)16.2Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %3.8Quick Ratio0Cash flow > EarningsN
Price/Sales3.15-y EBITDA Growth Rate %-1.5Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %18.3ROA % (ttm)8.7Higher Current Ratio y-yN
Dividend Yield %4.0Insider Buy (3m)0ROE % (ttm)15.0Less Shares Outstanding y-yN
Payout Ratio %90.0Shares Outstanding M2,642ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 48.09-10%Add 14.55%5,670,000
SNYPRIMECAP Management 2014-09-30 Add0.05%$50.89 - $57.29
($53.73)
$ 48.09-10%Add 29.21%3,891,356
SNYJean-Marie Eveillard 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 48.09-10%Reduce -94.39%34,157
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 48.09-9%Add 90.38%4,950,000
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 48.09-9%Add 21.59%3,011,646
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 48.09-9%Reduce -52.34%2,602,503
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 48.09-9%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 48.09-9%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 48.09-5%New holding, 247100 sh.247,100
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 48.09-5%New holding, 2600000 sh.2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 48.09-5%Add 65.83%9,804,594
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 48.09-5%Add 22.72%27,790,116
SNYNWQ Managers 2014-03-31 Reduce-0.17%$47.77 - $53.63
($50.68)
$ 48.09-5%Reduce -6.39%5,460,055
SNYHOTCHKIS & WILEY 2013-12-31 Add0.27%$48.75 - $54
($51.57)
$ 48.09-7%Add 23.53%5,912,375
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 48.09-7%Add 18.29%2,013,300
SNYNWQ Managers 2013-12-31 Add0.19%$48.75 - $54
($51.57)
$ 48.09-7%Add 7.52%5,832,760
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 48.09-7%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 48.09-6%Add 312.86%21,466,988
SNYHOTCHKIS & WILEY 2013-09-30 Add0.26%$47.64 - $53.24
($50.87)
$ 48.09-6%Add 31.71%4,786,334
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 48.09-6%Add 32.22%5,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY PRIMECAP Management 2014-09-303,891,3560.150.23+29.21%
SNY Bill Nygren 2014-09-305,670,0000.212.1+14.55%
SNY Charles Brandes 2014-09-302,248,9020.091.7+3.05%
SNY Mario Gabelli 2014-09-304,58000+1.78%
SNY HOTCHKIS & WILEY 2014-09-309,895,5210.372+1.26%
SNY Ken Fisher 2014-09-3013,145,6470.51.6+0.51%
SNY Warren Buffett 2014-09-303,905,8750.150.2
SNY Scott Black 2014-09-30178,4100.011.4-0.32%
SNY Dodge & Cox 2014-09-3043,267,0041.642.3-0.65%
SNY James Barrow 2014-09-3028,293,7231.072.2-0.82%
SNY NWQ Managers 2014-09-302,409,0400.091.5-7.43%
SNY Third Avenue Management 2014-09-3012,30600.02-8.18%
SNY Jean-Marie Eveillard 2014-09-3034,15700-94.39%
SNY Bill Nygren 2014-06-304,950,0000.191.9+90.38%
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-03-25Buy344,448$66.88-28.1view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67526.99view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      The Top 5 European Stocks Held During Q3 Nov 25 2014 
      Guru Stocks at 52-Week Lows: IBM, SNY, SAN, RIO, E Nov 09 2014 
      Guru Stocks at 52-Week Lows: IBM, BBL, SNY, SAN, RIO Nov 04 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      The MS Global Franchise Fund's Top Five Stocks Sep 10 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 


      More From Other Websites
      Sanofi's (SNY) Cerdelga a Step Closer to European Approval Nov 24 2014
      Sanofi Shakes Off Patent Losses Nov 24 2014
      Can New Launches Offset Sanofi's Soft Diabetes Business? Nov 21 2014
      MannKind's Afrezza Remains in Sanofi's Plans, RBC Says Nov 21 2014
      AbbVie, Celgene, Sanofi Drugs Get EU Endorsements Nov 21 2014
      Fighting kids' cancer, one voucher at a time Nov 21 2014
      European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules Nov 21 2014
      Regeneron & Sanofi Present Positive Data on PCSK9 Drug Nov 20 2014
      Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
      Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
      Sanofi's New Medicines day Nov 20 2014
      New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System Nov 20 2014
      Zacks Industry Outlook Highlights: Mylan, Sanofi, Amgen, Biogen, and Actavis Nov 20 2014
      Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
      Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
      Sanofi Outlines Next Wave of Innovative Medicines and Vaccines Nov 20 2014
      Will The IMPROVE-IT Results Impact The Thinking Of The FDA And Payers On LDL-Cholesterol Lowering... Nov 19 2014
      Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab... Nov 19 2014
      Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab... Nov 19 2014
      Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association Nov 18 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK